转化医学

订阅

MedSci主页 / 所有栏目 / 转化医学

英国癌症研究中心携手Bicycle Therapeutics进行实体瘤临床试验

2016-12-21 佚名 生物谷

临床实验
关注

英国癌症研究中心药物研发中心将资助Bicycle Therapeutics研发的二环肽偶联药物BT1718在晚期实体瘤病人身上进行1a/1b期临床试验，这项临床试验将由英国癌症研究中心和Bicycle一起管理进行。 BT17181是一种靶向膜型1类基质金属蛋白酶（MT1-MTP）的新药，这种蛋白质在三阴性乳腺癌、非小细胞肺癌等一系列实体瘤中高表达。 这项临床试验的项目负责人Udai Ban


英国癌症研究中心药物研发中心将资助Bicycle Therapeutics研发的二环肽偶联药物BT1718在晚期实体瘤病人身上进行1a/1b期临床试验，这项临床试验将由英国癌症研究中心和Bicycle一起管理进行。

BT17181是一种靶向膜型1类基质金属蛋白酶（MT1-MTP）的新药，这种蛋白质在三阴性乳腺癌、非小细胞肺癌等一系列实体瘤中高表达。

这项临床试验的项目负责人Udai Banaji博士说道：“参与BT1718的临床试验，我感到很激动。鉴于这个新药令人兴奋的临床前数据，我希望能够评估这个新药的临床价值，它是首个通过偶联二环肽以特异性靶向肿瘤细胞的药物。”

Bicycle CEO Kevin Lee说道：“通过这项重要的合作我们可以推进BT1718进入1期临床试验，我们还可以获得强有力的数据支持我们进一步深入研究。能与英国癌症研究中心建立合作关系我们非常激动，因为我们可以使用他们广泛的合作网络深入探索这类新的抗癌药物并将之推向临床。”

英国癌症研究中心药物研发主任Nigel Blackburn博士则表示：“找到治疗癌症的新方法是我们的重要研究领域。通过这项合作，我们希望可以加速药物开发，为那些急需新药治疗的病人带来更多新的治疗选择方案。”

参考原文：

Cancer Research UK, Bicycle Therapeutics partner to trial new therapy for advanced solid tumours

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1738801, encodeId=c7df1e3880199, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon May 08 18:05:00 CST 2017, time=2017-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974349, encodeId=99b019e4349d3, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Thu Oct 12 18:05:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726253, encodeId=e4321e2625366, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Mar 18 05:05:00 CST 2017, time=2017-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780330, encodeId=ced91e80330f2, content=<a href='/topic/show?id=59cd339631' target=_blank style='color:#2F92EE;'>#Bicycle#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3396, encryptionId=59cd339631, topicName=Bicycle)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Fri Aug 25 15:05:00 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=166897, encodeId=54f916689efd, content=学习了，加油！, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRvvXNvY0kOJqn4liar3Q6V6yPuEIawCVUyP3jVADh5icIz0ibrsxia6fKAqKsDr33jPWrjqM3D7wcRNu/0, createdBy=5a881701729, createdName=小树熊, createdTime=Sat Dec 31 00:04:21 CST 2016, time=2016-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350800, encodeId=d4541350800e5, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Dec 23 04:05:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514168, encodeId=3ed415141682f, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Fri Dec 23 04:05:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623576, encodeId=b40c16235e6fc, content=<a href='/topic/show?id=dd898e10879' target=_blank style='color:#2F92EE;'>#英国癌症研究中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87108, encryptionId=dd898e10879, topicName=英国癌症研究中心)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f6b20558327, createdName=yankaienglish, createdTime=Fri Dec 23 04:05:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=164882, encodeId=d14e164882dc, content=挺好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/25/ba882cb566d3be250a05e2a69b80f2c9.jpg, createdBy=32881678798, createdName=小M医师, createdTime=Thu Dec 22 14:10:05 CST 2016, time=2016-12-22, status=1, ipAttribution=)]
    2017-05-08 124988c7m106暂无昵称

    #ERA#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1738801, encodeId=c7df1e3880199, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon May 08 18:05:00 CST 2017, time=2017-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974349, encodeId=99b019e4349d3, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Thu Oct 12 18:05:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726253, encodeId=e4321e2625366, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Mar 18 05:05:00 CST 2017, time=2017-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780330, encodeId=ced91e80330f2, content=<a href='/topic/show?id=59cd339631' target=_blank style='color:#2F92EE;'>#Bicycle#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3396, encryptionId=59cd339631, topicName=Bicycle)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Fri Aug 25 15:05:00 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=166897, encodeId=54f916689efd, content=学习了，加油！, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRvvXNvY0kOJqn4liar3Q6V6yPuEIawCVUyP3jVADh5icIz0ibrsxia6fKAqKsDr33jPWrjqM3D7wcRNu/0, createdBy=5a881701729, createdName=小树熊, createdTime=Sat Dec 31 00:04:21 CST 2016, time=2016-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350800, encodeId=d4541350800e5, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Dec 23 04:05:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514168, encodeId=3ed415141682f, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Fri Dec 23 04:05:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623576, encodeId=b40c16235e6fc, content=<a href='/topic/show?id=dd898e10879' target=_blank style='color:#2F92EE;'>#英国癌症研究中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87108, encryptionId=dd898e10879, topicName=英国癌症研究中心)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f6b20558327, createdName=yankaienglish, createdTime=Fri Dec 23 04:05:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=164882, encodeId=d14e164882dc, content=挺好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/25/ba882cb566d3be250a05e2a69b80f2c9.jpg, createdBy=32881678798, createdName=小M医师, createdTime=Thu Dec 22 14:10:05 CST 2016, time=2016-12-22, status=1, ipAttribution=)]
    2017-10-12 ms24272190615788285182

    #Therapeutic#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1738801, encodeId=c7df1e3880199, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon May 08 18:05:00 CST 2017, time=2017-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974349, encodeId=99b019e4349d3, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Thu Oct 12 18:05:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726253, encodeId=e4321e2625366, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Mar 18 05:05:00 CST 2017, time=2017-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780330, encodeId=ced91e80330f2, content=<a href='/topic/show?id=59cd339631' target=_blank style='color:#2F92EE;'>#Bicycle#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3396, encryptionId=59cd339631, topicName=Bicycle)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Fri Aug 25 15:05:00 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=166897, encodeId=54f916689efd, content=学习了，加油！, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRvvXNvY0kOJqn4liar3Q6V6yPuEIawCVUyP3jVADh5icIz0ibrsxia6fKAqKsDr33jPWrjqM3D7wcRNu/0, createdBy=5a881701729, createdName=小树熊, createdTime=Sat Dec 31 00:04:21 CST 2016, time=2016-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350800, encodeId=d4541350800e5, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Dec 23 04:05:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514168, encodeId=3ed415141682f, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Fri Dec 23 04:05:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623576, encodeId=b40c16235e6fc, content=<a href='/topic/show?id=dd898e10879' target=_blank style='color:#2F92EE;'>#英国癌症研究中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87108, encryptionId=dd898e10879, topicName=英国癌症研究中心)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f6b20558327, createdName=yankaienglish, createdTime=Fri Dec 23 04:05:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=164882, encodeId=d14e164882dc, content=挺好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/25/ba882cb566d3be250a05e2a69b80f2c9.jpg, createdBy=32881678798, createdName=小M医师, createdTime=Thu Dec 22 14:10:05 CST 2016, time=2016-12-22, status=1, ipAttribution=)]
    2017-03-18 feather89

    #PE#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1738801, encodeId=c7df1e3880199, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon May 08 18:05:00 CST 2017, time=2017-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974349, encodeId=99b019e4349d3, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Thu Oct 12 18:05:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726253, encodeId=e4321e2625366, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Mar 18 05:05:00 CST 2017, time=2017-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780330, encodeId=ced91e80330f2, content=<a href='/topic/show?id=59cd339631' target=_blank style='color:#2F92EE;'>#Bicycle#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3396, encryptionId=59cd339631, topicName=Bicycle)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Fri Aug 25 15:05:00 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=166897, encodeId=54f916689efd, content=学习了，加油！, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRvvXNvY0kOJqn4liar3Q6V6yPuEIawCVUyP3jVADh5icIz0ibrsxia6fKAqKsDr33jPWrjqM3D7wcRNu/0, createdBy=5a881701729, createdName=小树熊, createdTime=Sat Dec 31 00:04:21 CST 2016, time=2016-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350800, encodeId=d4541350800e5, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Dec 23 04:05:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514168, encodeId=3ed415141682f, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Fri Dec 23 04:05:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623576, encodeId=b40c16235e6fc, content=<a href='/topic/show?id=dd898e10879' target=_blank style='color:#2F92EE;'>#英国癌症研究中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87108, encryptionId=dd898e10879, topicName=英国癌症研究中心)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f6b20558327, createdName=yankaienglish, createdTime=Fri Dec 23 04:05:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=164882, encodeId=d14e164882dc, content=挺好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/25/ba882cb566d3be250a05e2a69b80f2c9.jpg, createdBy=32881678798, createdName=小M医师, createdTime=Thu Dec 22 14:10:05 CST 2016, time=2016-12-22, status=1, ipAttribution=)]
    2017-08-25 肉我只吃一口

    #Bicycle#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1738801, encodeId=c7df1e3880199, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon May 08 18:05:00 CST 2017, time=2017-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974349, encodeId=99b019e4349d3, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Thu Oct 12 18:05:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726253, encodeId=e4321e2625366, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Mar 18 05:05:00 CST 2017, time=2017-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780330, encodeId=ced91e80330f2, content=<a href='/topic/show?id=59cd339631' target=_blank style='color:#2F92EE;'>#Bicycle#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3396, encryptionId=59cd339631, topicName=Bicycle)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Fri Aug 25 15:05:00 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=166897, encodeId=54f916689efd, content=学习了，加油！, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRvvXNvY0kOJqn4liar3Q6V6yPuEIawCVUyP3jVADh5icIz0ibrsxia6fKAqKsDr33jPWrjqM3D7wcRNu/0, createdBy=5a881701729, createdName=小树熊, createdTime=Sat Dec 31 00:04:21 CST 2016, time=2016-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350800, encodeId=d4541350800e5, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Dec 23 04:05:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514168, encodeId=3ed415141682f, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Fri Dec 23 04:05:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623576, encodeId=b40c16235e6fc, content=<a href='/topic/show?id=dd898e10879' target=_blank style='color:#2F92EE;'>#英国癌症研究中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87108, encryptionId=dd898e10879, topicName=英国癌症研究中心)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f6b20558327, createdName=yankaienglish, createdTime=Fri Dec 23 04:05:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=164882, encodeId=d14e164882dc, content=挺好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/25/ba882cb566d3be250a05e2a69b80f2c9.jpg, createdBy=32881678798, createdName=小M医师, createdTime=Thu Dec 22 14:10:05 CST 2016, time=2016-12-22, status=1, ipAttribution=)]
    2016-12-31 小树熊

    学习了，加油！

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1738801, encodeId=c7df1e3880199, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon May 08 18:05:00 CST 2017, time=2017-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974349, encodeId=99b019e4349d3, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Thu Oct 12 18:05:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726253, encodeId=e4321e2625366, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Mar 18 05:05:00 CST 2017, time=2017-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780330, encodeId=ced91e80330f2, content=<a href='/topic/show?id=59cd339631' target=_blank style='color:#2F92EE;'>#Bicycle#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3396, encryptionId=59cd339631, topicName=Bicycle)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Fri Aug 25 15:05:00 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=166897, encodeId=54f916689efd, content=学习了，加油！, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRvvXNvY0kOJqn4liar3Q6V6yPuEIawCVUyP3jVADh5icIz0ibrsxia6fKAqKsDr33jPWrjqM3D7wcRNu/0, createdBy=5a881701729, createdName=小树熊, createdTime=Sat Dec 31 00:04:21 CST 2016, time=2016-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350800, encodeId=d4541350800e5, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Dec 23 04:05:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514168, encodeId=3ed415141682f, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Fri Dec 23 04:05:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623576, encodeId=b40c16235e6fc, content=<a href='/topic/show?id=dd898e10879' target=_blank style='color:#2F92EE;'>#英国癌症研究中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87108, encryptionId=dd898e10879, topicName=英国癌症研究中心)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f6b20558327, createdName=yankaienglish, createdTime=Fri Dec 23 04:05:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=164882, encodeId=d14e164882dc, content=挺好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/25/ba882cb566d3be250a05e2a69b80f2c9.jpg, createdBy=32881678798, createdName=小M医师, createdTime=Thu Dec 22 14:10:05 CST 2016, time=2016-12-22, status=1, ipAttribution=)]
    2016-12-23 zhaojie88

    #therapeutics#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1738801, encodeId=c7df1e3880199, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon May 08 18:05:00 CST 2017, time=2017-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974349, encodeId=99b019e4349d3, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Thu Oct 12 18:05:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726253, encodeId=e4321e2625366, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Mar 18 05:05:00 CST 2017, time=2017-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780330, encodeId=ced91e80330f2, content=<a href='/topic/show?id=59cd339631' target=_blank style='color:#2F92EE;'>#Bicycle#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3396, encryptionId=59cd339631, topicName=Bicycle)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Fri Aug 25 15:05:00 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=166897, encodeId=54f916689efd, content=学习了，加油！, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRvvXNvY0kOJqn4liar3Q6V6yPuEIawCVUyP3jVADh5icIz0ibrsxia6fKAqKsDr33jPWrjqM3D7wcRNu/0, createdBy=5a881701729, createdName=小树熊, createdTime=Sat Dec 31 00:04:21 CST 2016, time=2016-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350800, encodeId=d4541350800e5, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Dec 23 04:05:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514168, encodeId=3ed415141682f, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Fri Dec 23 04:05:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623576, encodeId=b40c16235e6fc, content=<a href='/topic/show?id=dd898e10879' target=_blank style='color:#2F92EE;'>#英国癌症研究中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87108, encryptionId=dd898e10879, topicName=英国癌症研究中心)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f6b20558327, createdName=yankaienglish, createdTime=Fri Dec 23 04:05:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=164882, encodeId=d14e164882dc, content=挺好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/25/ba882cb566d3be250a05e2a69b80f2c9.jpg, createdBy=32881678798, createdName=小M医师, createdTime=Thu Dec 22 14:10:05 CST 2016, time=2016-12-22, status=1, ipAttribution=)]
    2016-12-23 小华子

    #癌症研究#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1738801, encodeId=c7df1e3880199, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon May 08 18:05:00 CST 2017, time=2017-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974349, encodeId=99b019e4349d3, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Thu Oct 12 18:05:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726253, encodeId=e4321e2625366, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Mar 18 05:05:00 CST 2017, time=2017-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780330, encodeId=ced91e80330f2, content=<a href='/topic/show?id=59cd339631' target=_blank style='color:#2F92EE;'>#Bicycle#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3396, encryptionId=59cd339631, topicName=Bicycle)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Fri Aug 25 15:05:00 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=166897, encodeId=54f916689efd, content=学习了，加油！, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRvvXNvY0kOJqn4liar3Q6V6yPuEIawCVUyP3jVADh5icIz0ibrsxia6fKAqKsDr33jPWrjqM3D7wcRNu/0, createdBy=5a881701729, createdName=小树熊, createdTime=Sat Dec 31 00:04:21 CST 2016, time=2016-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350800, encodeId=d4541350800e5, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Dec 23 04:05:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514168, encodeId=3ed415141682f, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Fri Dec 23 04:05:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623576, encodeId=b40c16235e6fc, content=<a href='/topic/show?id=dd898e10879' target=_blank style='color:#2F92EE;'>#英国癌症研究中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87108, encryptionId=dd898e10879, topicName=英国癌症研究中心)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f6b20558327, createdName=yankaienglish, createdTime=Fri Dec 23 04:05:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=164882, encodeId=d14e164882dc, content=挺好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/25/ba882cb566d3be250a05e2a69b80f2c9.jpg, createdBy=32881678798, createdName=小M医师, createdTime=Thu Dec 22 14:10:05 CST 2016, time=2016-12-22, status=1, ipAttribution=)]
    2016-12-23 yankaienglish

    #英国癌症研究中心#

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1738801, encodeId=c7df1e3880199, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon May 08 18:05:00 CST 2017, time=2017-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974349, encodeId=99b019e4349d3, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Thu Oct 12 18:05:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726253, encodeId=e4321e2625366, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Mar 18 05:05:00 CST 2017, time=2017-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780330, encodeId=ced91e80330f2, content=<a href='/topic/show?id=59cd339631' target=_blank style='color:#2F92EE;'>#Bicycle#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3396, encryptionId=59cd339631, topicName=Bicycle)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Fri Aug 25 15:05:00 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=166897, encodeId=54f916689efd, content=学习了，加油！, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRvvXNvY0kOJqn4liar3Q6V6yPuEIawCVUyP3jVADh5icIz0ibrsxia6fKAqKsDr33jPWrjqM3D7wcRNu/0, createdBy=5a881701729, createdName=小树熊, createdTime=Sat Dec 31 00:04:21 CST 2016, time=2016-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350800, encodeId=d4541350800e5, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Dec 23 04:05:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514168, encodeId=3ed415141682f, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Fri Dec 23 04:05:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623576, encodeId=b40c16235e6fc, content=<a href='/topic/show?id=dd898e10879' target=_blank style='color:#2F92EE;'>#英国癌症研究中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87108, encryptionId=dd898e10879, topicName=英国癌症研究中心)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f6b20558327, createdName=yankaienglish, createdTime=Fri Dec 23 04:05:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=164882, encodeId=d14e164882dc, content=挺好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/25/ba882cb566d3be250a05e2a69b80f2c9.jpg, createdBy=32881678798, createdName=小M医师, createdTime=Thu Dec 22 14:10:05 CST 2016, time=2016-12-22, status=1, ipAttribution=)]
    2016-12-22 小M医师

    挺好的

    0

相关资讯

HIV-1抗体疗法重回临床应用

生物谷BIOON/ --人类免疫缺陷病毒（HIV）感染的第一次报道距今已有35年，在此期间，HIV肆虐全球，感染了将近4000万人口。科学家不断努力使得抗病毒疗法飞快地发展，如今复合型的药物治疗已经成为HIV治疗的常规方法，用于维持患者的健康水平与寿命。然而，HIV巧妙地躲避宿主免疫系统的能力以及它可以长期处于静息状态的特征使得研发特异性的疫苗十分困难。利用抗体进行HIV的治疗的概念很早以前就被提

研究型医院：提高转化医学与临床实验的研究水平

生物医学科学技术的飞速发展促进了许多基础生物医学研究的重大的突破。医学研究者对许多疾病的发病机制从其分子生物学，细胞生物学，遗传学和基因组学的水平上都有了前所未有的深入理解，并积累了大量的生物学和基础医学研究的数据。然而，如何将这些研究成果迅速转化为可以诊治人类疾病的有效方法，仍然是当今医学科研工作者所面临的难题之一。新兴的转化医学(Translational Medicine)，将医学和生物学等